Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Sunbelt Securities Inc.

Sunbelt Securities Inc. decreased its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 13.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 160,225 shares of the biotechnology company’s stock after selling 25,050 shares during the quarter. Sunbelt Securities Inc.’s holdings in Aurinia Pharmaceuticals were worth $915,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. HighMark Wealth Management LLC raised its stake in Aurinia Pharmaceuticals by 3.0% during the first quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 2,197 shares in the last quarter. ProShare Advisors LLC raised its stake in Aurinia Pharmaceuticals by 9.1% during the first quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 2,873 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $30,000. The Manufacturers Life Insurance Company raised its stake in Aurinia Pharmaceuticals by 10.0% during the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 4,808 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Aurinia Pharmaceuticals by 7.1% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 75,787 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 5,043 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insider Activity

In related news, insider Scott Michael Habig sold 18,249 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on AUPH. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Stock Up 0.7 %

NASDAQ:AUPH opened at $7.33 on Tuesday. The firm has a market capitalization of $1.05 billion, a PE ratio of -17.05 and a beta of 1.44. The stock has a 50 day moving average of $6.36 and a 200-day moving average of $5.67. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.05. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $57.10 million during the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The business’s revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.08) earnings per share. Analysts predict that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.